1 / 60

Program Goals

Program Goals. Introduction. Using Vaccines in the Treatment of NSCLC. Vaccine Approach in NSCLC Targeting Tumor Antigens. Vaccines Evaluated in Phase 3 Lung Cancer Trials Study Designs. Vaccines Evaluated in Phase 3 Lung Cancer Trials (cont) Study Designs.

gisela-randall
Download Presentation

Program Goals

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Program Goals

  2. Introduction

  3. Using Vaccines in the Treatment of NSCLC

  4. Vaccine Approach in NSCLC Targeting Tumor Antigens

  5. Vaccines Evaluated in Phase 3 Lung Cancer TrialsStudy Designs

  6. Vaccines Evaluated in Phase 3 Lung Cancer Trials (cont)Study Designs

  7. Vaccines Evaluated in Phase 3 Lung Cancer TrialsStudy Results

  8. Vaccines Evaluated in Phase 3 Lung Cancer Trials (cont)Study Results

  9. Using Vaccines in the Treatment of NSCLC: Key Points

  10. Immune Checkpoints and Their Inhibition

  11. Immune Checkpoint Blockade Approach in NSCLCTargeting the Immune System

  12. CTLA-4: Upregulation and Blockade

  13. CTLA-4 in the Immune Response

  14. PD-1 and PD-L1 and PD-1/PD-L1 Blockade

  15. PD-1/PD-L1 in the Immune Response

  16. CTLA-4 and PD-1 Signaling Pathways

  17. Antibody Blockade of Immune Checkpoints

  18. Immune Checkpoints and Their Inhibition: Key Points

  19. Immune-related Response Criteria

  20. Evaluating Response to Immunotherapeutic Agents in Solid TumorsImmune-Related Response Criteria

  21. Defining Response WHO vs irRC

  22. Defining Response (cont) WHO vs irRC

  23. Patterns of Response to Cancer Immunotherapy

  24. Immune-related Response Criteria:Key Points

  25. Clinical Studies of Immune Checkpoint Inhibitor Therapy in Advanced NSCLC

  26. Ipilimumab + Chemotherapy in Advanced NSCLCDesign of Phase 2 Trial

  27. Ipilimumab + Chemotherapy in Advanced NSCLCResults

  28. Ipilimumab + ChemotherapyHistology Subgroup Analysis

  29. Anti-PD-1 and Anti-PD-L1 Monotherapy in Heavily Pretreated Patients With Advanced NSCLCEfficacy in Phase 1 Trials

  30. Anti-PD-1 and Anti-PD-L1 Monotherapy in Heavily Pretreated Patients With Advanced NSCLCSafety in Phase 1 Trials

  31. Anti-PD-1 and Anti-PD-L1 Monotherapy in Heavily Pretreated Patients With Advanced NSCLCSafety in Phase 1 Studies

  32. Phase 1 Study of Nivolumab in Heavily Pretreated Pts With Advanced NSCLCHistology Subgroup Analysis

  33. Phase 1 Studies of Single Agent Immunotherapies in First-Line Setting

  34. Combinations With Immunotherapy in Advanced NSCLC

  35. Combinations With Immunotherapy in Advanced NSCLC (cont)

  36. Clinical Studies of Immune Checkpoint Inhibitor Therapy in Advanced NSCLC: Key Points

  37. Tumor PD-L1 Level as a Biomarker for Response

  38. Relationship Between PD-L1 Tumor Status and Response to PD-1 and PD-L1 Inhibitors

  39. Relationship Between PD-L1 Tumor Status and Response to PD-1 and PD-L1 Inhibitors (cont)

  40. Other Immune Checkpoint Targets

  41. Some Other Immune Checkpoint Protein Targets

  42. Some Other Immune Checkpoint Protein Targets (cont)

  43. Ongoing Phase 3 Clinical Trials of Immune Checkpoint Inhibitor Therapy in Advanced NSCLC

  44. Some Ongoing Phase 3 Trials Second Line

  45. Some Ongoing Phase 3 Trials (cont) Second Line

  46. Some Ongoing Phase 3 TrialsFirst Line

  47. Program Summary

  48. Abbreviations

  49. Abbreviations (cont)

More Related